Skip to Content

AVITA Medical Inc AVHHL

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Avita Therapeutics is a single product company, the RECELL system, an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes thus avoiding or reducing the need for skin grafts. The device is approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft tissue wounds and vitiligo underway. It is currently in roll-out across the approximately 136 burn centres in the U.S. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories. It is expected to gain approval and launch in Japan via distribution partner Cosmotec shortly. Avita is domiciled, and has its primary listing, in the U.S.

Contact
28159 Avenue Stanford, Suite 220, Valencia
Los Angeles, CA, 91355
T +1 661 367-9170
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Dec 31, 2020
Fiscal Year End Jun 30, 2021
Stock Type Distressed
Employees 98